Drugs / Stibium metallicum praeparatum 6x
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04715542 | Aug 2026 → Aug 2028 expected | chemotherapy-induced neuropathy | University of Bern | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Stibium metallicum praeparatum 6x | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04715542 ↗ |
| Known as | Antimon | “This study investigates the efficacy and tolerance of Stibium metallicum praeparatum 6x (Weleda), also known as Antimon, to prevent paclitaxel-induced peripheral neuropathy as...” NCT04715542 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “is listed by Swissmedic as an authorized anthroposophic medicinal product” NCT04715542 ↗ |
| Route | Subcutaneous | “subcutaneous injections” NCT04715542 ↗ |